EICHORCondition: Peripheral T Cell Lymphoma · Sponsor: Hospices Civils de Lyon
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Peripheral T-cell lymphoma (PTCL) encompasses a broad range of post-thymic (i.e., mature) sub-entities as defined by the 2017 WHO classification. The most common entities are angioimmunoblastic T-cell lymphoma (AITL) and other Tfh-phenotype PTCL or PTCL not otherwise specified (NOS), each representing approximately 20 to 25% of mature T- and NK/T-cell lymphomas. Compared to their B-cell counterparts, most PTCL confer dismal prognosis. In fact, except for anaplastic lymphoma kinase (ALK)-positive systemic anaplastic large cell lymphoma (sALCL), 10-year overall survival for patients with PTCL barely exceeds 30%. Given the infrequency and the heterogeneity of these malignancies, no real consensus on first-line treatment has been established for most PTCL. The place of autologous stem cell transplantation (ASCT) as a consolidation procedure for patients with PTCL achieving a complete metabolic response after induction is still highly debated. ESMO recommendations and recent guidelines from a committee of the American Society for Blood and Marrow Transplantation currently propose ASCT as first-line therapy for transplant-eligible patients for all patients reaching at least a partial response (PR) after induction. NCCN guidelines (version 2.2017) recommend ASCT or observation in case of metabolic CR but salvage regimen in case of residual disease after induction.
This description comes directly from the study's public registry record.
Emmanuel BACHY, Pr · +33(0) 4 78 86 22 05 · emmanuel.bachy@chu-lyon.fr
Rémy GRESSIN, Dr · +33 (0)4 76 76 57 12 · rgressin@chu-grenoble.fr
Always discuss trial participation with your own doctor first.
| Chu D'Amiens - Hopital Sud | Amiens, France | Not Yet Recruiting |
| Chu D'Angers | Angers, France | Not Yet Recruiting |
| Ch Victor Dupouy | Argenteuil, France | Not Yet Recruiting |
| Ch D'Avignon - Hopital Henri Duffaut | Avignon, France | Not Yet Recruiting |
| Ch de La Cote Basque | Bayonne, France | Not Yet Recruiting |
| Service d'Onco-radiolothérapie, Polyclinique Bordeaux Nord Aquitaine | Bordeaux, France | Not Yet Recruiting |
| Ch Metropole Savoie - Site Chambery | Chambéry, France | Not Yet Recruiting |
| Chu Estaing | Clermont-Ferrand, France | Not Yet Recruiting |
| Ch Alpes Leman | Contamine-sur-Arve, France | Not Yet Recruiting |
| Hopital Henri Mondor | Créteil, France | Not Yet Recruiting |
| René Olivier Casasnovas | Dijon, France | Not Yet Recruiting |
| CHU Francois MITTERRAND | Dijon, France | Not Yet Recruiting |
+ 36 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05444712